BioArctic AB (LTS:0RV2) Total Equity: kr2,016 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RV2 BioArctic AB LTS:0RV2
56 GF Score
Price kr334.30
! 7 Warning Signs
View Full Analysis

What is BioArctic AB Total Equity?

BioArctic AB LTS:0RV2 56 Total Equity is kr2,016 Mil as of Jun. 2026. GuruFocus rates LTS:0RV2 with a GF Score™ of 56/100. The stock has 7 warning signs investors should review.

BioArctic AB's total equity for the quarter that ended in Jun. 2026 was kr2,016 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BioArctic AB Total Equity Historical Data

* Premium members only.

The historical data trend for BioArctic AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioArctic AB Total Equity Chart

BioArctic AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 788.68 786.24 1,046.58 894.94 1,967.08

BioArctic AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,036.08 1,969.28 1,967.08 2,198.04 2,016.26
LTS:0RV2
56GF Score
BioArctic AB LTS:0RV2
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioArctic AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BioArctic AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2575.228-608.145
=1,967

BioArctic AB's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=2819.038-802.777
=2,016

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr2,016 Mil mean?
BioArctic AB (LTS:0RV2) has a Total Equity of kr2,016 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for BioArctic AB and its competitors.
Is BioArctic AB's Total Equity too high?
BioArctic AB's current Total Equity is kr2,016 Mil. Overall, BioArctic AB has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's Total Equity compare to VRTX and REGN?
BioArctic AB's Total Equity of kr2,016 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for BioArctic AB and its competitors. BioArctic AB's current Total Equity is kr2,016 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
BioArctic AB (LTS:0RV2) has a current Total Equity of kr2,016 Mil. The current Total Equity is kr2,016 Mil. BioArctic AB's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For BioArctic AB (LTS:0RV2), the current Total Equity is kr2,016 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioArctic AB Business Description

Address Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
56GF Score

Get the complete analysis for LTS:0RV2

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr334.30
Price